Roche vet named Gilead CEO — and Genentech boss moves to Switzerland — in shuffle of top Bay Area biotech execs
Gilead Sciences Inc. landed former Roche executive Daniel O'Day as its new CEO, and Genentech Inc.'s current CEO will take O'Day's role with Genentech's parent company in a game of musical chairs disclosed Sunday. The job shuffling has implicatio.....»»
From Akero to Zymergen, 20 Bay Area biotech companies to watch around JPM19
The 37th annual J.P. Morgan Healthcare Conference, along with the Biotech Showcase, Startup Health Festival and other conferences in San Francisco this week, feature big names, such as Amgen Inc., Gilead Sciences Inc., Bristol-Myers Squibb Co., Roche .....»»
Former Genentech execs — including ex-CEO Ian Clark — jump in with IPO-seeking gene therapy company
The company, with sites in the Bay Area, Philadelphia and London, also counts Genentech and a handful of other local biotechs as its competition......»»
Gilead"s virology drug head named CEO of East Coast biotech AlloVir
Dr. Diana Brainard, a 10-year veteran of Gilead Sciences Inc. who currently heads up the company's broad virology drug pipeline, will take over as CEO of a young cell therapy company backed by her soon-to-be former employer. Starting May 17, Brain.....»»
Hackers target Gilead in latest attack on Bay Area biotech, report says
Gilead Sciences Inc. employees were targeted over the past month by hackers, according to a report by Reuters. The news agency said the attacks, which representatives of three cybersecurity firms indicated had originated from Iran, preceded this wee.....»»
CBJ Morning Buzz: CLT workers said to have COVID-19 amid growing pressure for protective measures; Local leaders named among influential black execs
While large swaths of the Charlotte-area workforce are figuring out ways to get their jobs done remotely or with new operational protocols — and still others are laid off or furloughed — amid efforts to slow the spread of the novel coronavirus, s.....»»
Gilead Sciences names chief medical officer, from Genentech
Gilead Sciences Inc. said Monday it named Merdad Parsey its chief medical officer, effective Nov. 1. Parsey was most recently a senior vice p.....»»
Gilead names Merdad Parsey as chief medical officer, joining from Roche"s Genentech
This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»
Flush with cash after Gilead deal, founder pivots to real estate for his companies
Cell therapy pioneer and founder Arie Belldegrun has hatched a plan to find more space in the Bay Area for his portfolio of biotech companies......»»
Genentech, Roche vets aim new company"s $86.25 million IPO at cancer
A South San Francisco startup led by veterans of biotech stalwart Genentech Inc. and its parent company Roche wants to raise $86.25 million in an initial public offering. RAPT Therapeutics Inc. — known until May as FLX Bio Inc. — expects to us.....»»
BrewDog USA CEO moves to "disruption" role
BrewDog USA’s boss is moving into a global role as a new CEO takes the reins in the U.S. Tanisha Robinson has been named chief disruption officer for the Scotland-based brewery, a role in which she will work the company’s assorted startup ve.....»»
Biotech Analysis Central Pharma News: Roche Abandons Drug, Gilead"s Early Stage Bet, Vaxart"s Phase 2 Failure
Biotech Analysis Central Pharma News: Roche Abandons Drug, Gilead"s Early Stage Bet, Vaxart"s Phase 2 Failure.....»»
Roche steps up efficiency drive to take sting out of biosimilars
Roche , the world's biggest producer of cancer drugs, is stepping up cost cuts in an efficiency drive made unavoidable by competition from cut-price copies of three mega-brands from its famed U.S. Genentech biotech stable......»»
Genentech"s first scientist now focused on Bay Area"s latest biotech IPO
A South San Francisco company in a race to come up with a treatment for a deadly liver disease wants to raise $75 million in an initial public offering. NGM Biopharmaceuticals Inc. — backed by the venture capital firm managed by Dave Goeddel, the fi.....»»
Roche Executive to Be Named Gilead CEO
Gilead Sciences is planning to hire industry veteran Daniel O’Day to take the helm and help the drug company revive sales and recover from a disappointing deal......»»
Gilead Sciences hires Roche executive Daniel O"Day as CEO
Drugmaker Gilead Sciences Inc named Roche Holding AG executive Daniel O'Day as its new chief executive officer, the companies said on Monday......»»
Gilead Sciences snares Roche executive O"Day as CEO
Drugmaker Gilead Sciences Inc on Monday named Roche Holding AG executive Daniel O'Day as its new chief executive, tapping an industry veteran to fill a management vacuum......»»
Gilead Sciences snares Roche veteran O"Day as CEO
Drugmaker Gilead Sciences Inc on Monday named Roche Holding AG's Daniel O'Day as its new chief executive, tapping an industry veteran to fill a management vacuum......»»
New Gilead Sciences CEO Has "Breadth Of Experience" From Time At Roche, Says Bullish Raymond James
Research-based biopharmaceutical company Gilead Sciences, Inc. (NASDAQ: GILD) announced Monday it has named Daniel O'Day as its chairman of the board and CEO, ef Latest Ratings for GILD DateFirm.....»»
Six Minnesota businesswomen named to Inc. Magazine"s "Female Founders 250" list
Inc. Magazine revealed its sixth-annual Female Founders 250 list, denoting 250 women making moves in the entrepreneurial world. And on this year's list were several familiar faces to the Minnesota startup scene......»»
Anti-Trump sentiment strong among Milwaukee-area business execs
Many conservatives in southeast Wisconsin business donated to Nikki Haley and Ron DeSantis. What now?.....»»